What is BioCryst Pharmaceuticals's debt-to-assets?

BioCryst Pharmaceuticals (BCRX) reported debt-to-assets of 0.9× in Q1 2026.

How has BioCryst Pharmaceuticals's debt-to-assets changed year-over-year?

BioCryst Pharmaceuticals's debt-to-assets increased by 28.7% year-over-year, from 0.7× to 0.9×.

What is the long-term trend for BioCryst Pharmaceuticals's debt-to-assets?

Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's debt-to-assets has grown at a -42.1% compound annual growth rate (CAGR), from 0.4× to 0×.

What does debt-to-assets mean?

Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.

BioCryst Pharmaceuticals BCRX Debt-to-assets

Debt-to-assets at other companies

Ionis PharmaceuticalsIONS

0.2×+0.1×

Ultragenyx PharmaceuticalRARE

0×0.0×

ANI PharmaceuticalsANIP

0.2×0.0×

AnaptysBio, Inc.ANAB

0×—

BridgeBio PharmaBBIO

2.4×+2.4×

PVL

Palvella TherapeuticsPVLA

0×—

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Calculated from BioCryst Pharmaceuticals’s reported figures.

total debt/total assets=0.9×

Based on the most recent quarter.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's debt-to-assets?: BioCryst Pharmaceuticals (BCRX) reported debt-to-assets of 0.9× in Q1 2026.
How has BioCryst Pharmaceuticals's debt-to-assets changed year-over-year?: BioCryst Pharmaceuticals's debt-to-assets increased by 28.7% year-over-year, from 0.7× to 0.9×.
What is the long-term trend for BioCryst Pharmaceuticals's debt-to-assets?: Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's debt-to-assets has grown at a -42.1% compound annual growth rate (CAGR), from 0.4× to 0×.
What does debt-to-assets mean?: Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.